HSBC Posts Flat Quarterly Net Profit
The London-based bank said first-quarter net profit was largely flat as higher credit charges amid t…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
-12.9% vs SMA 50 · -14.7% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $733.1M $729.9M–$734.8M | — | $1.66 | — | ±1% | High12 |
FY2026(current) | $827.3M $821.1M–$833.9M | ▲ +12.8% | $1.97 | ▲ +18.2% | ±1% | High15 |
FY2027 | $948.5M $938.1M–$959.7M | ▲ +14.7% | $2.55 | ▲ +29.7% | ±16% | High14 |
The London-based bank said first-quarter net profit was largely flat as higher credit charges amid t…

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.